# A Proof of Concept Study of Maintenance Therapy With Tasquinimod in Patients With Metastatic Castrate-resistant Prostate Cancer Who Are Not Progressing After a First Line Docetaxel Based Chemotherapy

> **NCT01732549** · PHASE2 · TERMINATED · sponsor: **Ipsen** · enrollment: 144 (actual)

## Conditions studied

- Metastatic Castrate Resistant Prostate Cancer

## Interventions

- **DRUG:** Tasquinimod
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01732549
- **Lead sponsor:** Ipsen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2013-01
- **Primary completion:** 2015-02
- **Final completion:** 2015-05
- **Target enrollment:** 144 (ACTUAL)
- **Why stopped:** Development of tasquinimod in prostate cancer discontinued
- **Last updated:** 2019-11-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01732549

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01732549, "A Proof of Concept Study of Maintenance Therapy With Tasquinimod in Patients With Metastatic Castrate-resistant Prostate Cancer Who Are Not Progressing After a First Line Docetaxel Based Chemotherapy". Retrieved via AI Analytics 2026-09-04 from https://api.ai-analytics.org/clinical/NCT01732549. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*